The role of skin barrier function in atopic dermatitis: An update

Expert Review of Dermatology

Volumn 7, Issue 3, 2012, Pages 247-257

  Fölster Holst, Regina ^a   Dähnhardt Pfeiffer, Stephan ^b   Dähnhardt, Dorothee ^b   Proksch, Ehrhardt ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Microscopy Services Dähnhardt GmbH   (Germany)

Author keywords

atopic dermatitis; barrier function; filaggrin; lipids; proteases; tight junctions

Indexed keywords

CERAMIDE; CORTICOSTEROID; CYSTATIN; FILAGGRIN; KALLIKREIN; LORICRIN; PIMECROLIMUS; PLASMIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9; UROKINASE;

ATOPIC DERMATITIS; FILAGGRIN GENE; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INNATE IMMUNITY; LIPID ANALYSIS; LIPID METABOLISM; MUTATOR GENE; NONHUMAN; PATHOGENESIS; PERMEABILITY BARRIER; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SKIN FUNCTION; SKIN WATER LOSS; TIGHT JUNCTION;

EID: 84864029662     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/edm.12.17     Document Type: Review

References (102)

1. Boguniewicz M, Leung DY. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunol. Rev. 242(1), 233-246 (2011).
2. Flohr C, Williams HC. Epidemiology. In: ATOPIC Dermatitis (2nd Edition). Bieber T, Leung DYM (Eds). Informa Healthcare, NY, USA, 11-35 (2009).
3. Yamamoto M, Kamata Y, Iida T et al. Quantification of activated and total caspase-14 with newly developed ELISA systems in normal and atopic skin. J. Dermatol. Sci. 61(2), 110-117 (2011).
4. Oji V, Eckl KM, Aufenvenne K et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: Unraveling the peeling skin disease. Am. J. Hum. Genet. 87(2), 274-281 (2010).
5. Egberts F, Heinrich M, Jensen JM et al. Cathepsin D is involved in the regulation of transglutaminase 1 and epidermal differentiation. J. Cell. Sci. 117(Pt 11), 2295-2307 (2004).
6. Leclerc EA, Huchenq A, Mattiuzzo NR et al. Corneodesmosin gene ablation induces lethal skin-barrier disruption and hair-follicle degeneration related to desmosome dysfunction. J. Cell. Sci. 122(Pt 15), 2699-2709 (2009).
7. Proksch E, Fölster-Holst R, Jensen JM. Epidermal barrier in atopic dermatitis. In: ATOPIC Dermatitis (2nd Edition). Bieber T, Leung DYM (Eds). Informa Healthcare, NY, USA, 69-86 (2009).
8. Jensen JM, Fölster-Holst R, Baranowsky A et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J. Invest. Dermatol. 122(6), 1423-1431 (2004).
9. Jensen JM, Pfeiffer S, Witt M et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J. Allergy Clin. Immunol. 124(3 Suppl. 2), R19-R28 (2009).
10. Elias PM. Epidermal lipids, membranes, and keratinization. Int. J. Dermatol. 20(1), 1-19 (1981).
11. Holleran WM, Man MQ, Gao WN, Menon GK, Elias PM, Feingold KR. Sphingolipids are required for mammalian epidermal barrier function. Inhibition of sphingolipid synthesis delays barrier recovery after acute perturbation. J. Clin. Invest. 88(4), 1338-1345 (1991).
12. Janssens M, van Smeden J, Gooris GS et al. Lamellar lipid organization and ceramide composition in the stratum corneum of patients with atopic eczema. J. Invest. Dermatol. 131(10), 2136-2138 (2011).
13. Daehnhardt-Pfeiffer S, Surber C, Wilhelm KP et al. Noninvasive stratum corneum sampling and electron microscopical examination of skin barrier integrity: Pilot study with a topical glycerin formulation for atopic dermatitis. Skin Pharmacol. Physiol. 25(3), 155-161 (2012).
14. Dale BA, Holbrook KA, Steinert PM. Assembly of stratum corneum basic protein and keratin filaments in macrofibrils. Nature 276(5689), 729-731 (1978).
15. Candi E, Schmidt R, Melino G. The cornified envelope: A model of epidermal barrier in atopic dermatitis. Cell death in the skin. Nat. Rev. Mol. Cell Biol. 6, 328-340 (2005).
16. Kalinin A, Marekov LN, Steinert PM. Assembly of the epidermal cornified cell envelope. J. Cell. Sci. 114(Pt 17), 3069-3070 (2001).
17. Mlitz V, Latreille J, Gardinier S et al. Impact of filaggrin mutations on Raman spectra and biophysical properties of the stratum corneum in mild to moderate atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. doi: 10.1111/j.1468-3083.2011.04198.x. (2011) (Epub ahead of print).
18. Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatol Ther. 17(Suppl. 1), 43-48 (2004).
19. Gruber R, Elias PM, Crumrine D et al. Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and function. Am. J. Pathol. 178(5), 2252-2263 (2011).
20. Seguchi T, Cui CY, Kusuda S, Takahashi M, Aisu K, Tezuka T. Decreased expression of filaggrin in atopic skin. Arch. Dermatol. Res. 288(8), 442-446 (1996).
21. Howell MD, Kim BE, Gao P et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J. Allergy Clin. Immunol. 124(3 Suppl. 2), R7-R12 (2009).
22. Howell MD, Kim BE, Gao P et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J. Allergy Clin. Immunol. 120(1), 150-155 (2007).
23. Wang YH, Angkasekwinai P, Lu N et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J. Exp. Med. 204(8), 1837-1847 (2007).
24. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M. IL-25 in atopic dermatitis: A possible link between inflammation and skin barrier dysfunction? J. Invest. Dermatol. 131(1), 150-157 (2011).
25. Smith FJ, Irvine AD, Terron-Kwiatkowski A et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat. Genet. 38(3), 337-342 (2006).
26. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-offunction variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38(4), 441-446 (2006).
27. Ruether A, Stoll M, Schwarz T, Schreiber S, Fölster-Holst R. Filaggrin loss-offunction variant contributes to atopic dermatitis risk in the population of Northern Germany. Br. J. Dermatol. 155(5), 1093-1094 (2006).
28. Weidinger S, Illig T, Baurecht H et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J. Allergy Clin. Immunol. 118(1), 214-219 (2006).
29. Brown SJ, McLean WH. Eczema genetics: Current state of knowledge and future goals. J. Invest. Dermatol. 129(3), 543-552 (2009).
30. Nomura T, Akiyama M, Sandilands A et al. Prevalent and rare mutations in the gene encoding filaggrin in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J. Invest. Dermatol. 129(5), 1302-1305 (2009).
31. Enomoto H, Hirata K, Otsuka K et al. Filaggrin null mutations are associated with atopic dermatitis and elevated levels of IgE in the Japanese population: A family and case-control study. J. Hum. Genet. 53(7), 615-621 (2008).
32. Chen H, Ho JC, Sandilands A et al. Unique and recurrent mutations in the filaggrin gene in Singaporean Chinese patients with ichthyosis vulgaris. J. Invest. Dermatol. 128(7), 1669-1675 (2008).
33. Brown SJ, McLean WH. One remarkable molecule: Filaggrin. J. Invest. Dermatol. 132(3 Pt 2), 751-762 (2012).
34. Smith FJ, Irvine AD, Terron-Kwiatkowski A et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat. Genet. 38(3), 337-342 (2006).
35. Bremmer SF, Hanifin JM, Simpson EL. Clinical detection of ichthyosis vulgaris in an atopic dermatitis clinic: Implications for allergic respiratory disease and prognosis. J. Am. Acad. Dermatol. 59(1), 72-78 (2008).
36. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 9(5), 437-444 (2009).
37. Thyssen JP, Ross-Hansen K, Johansen JD et al. Filaggrin loss-of-function mutation R501X and 2282del4 carrier status is associated with fissured skin on the hands: Results from a cross-sectional population study. Br. J. Dermatol. 166(1), 46-53 (2012).
38. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: A disease caused by innate immune defects? J. Invest. Dermatol. 129(1), 14-30 (2009).
39. Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol. Int. 60(1), 1-9 (2011).
40. Filipiak-Pittroff B, Schnopp C, Berdel D et al.; GINIplus and LISAplus study groups. Predictive value of food sensitization and filaggrin mutations in children with eczema. J. Allergy Clin. Immunol. 128(6), 1235-1241.e5 (2011).
41. Vercelli D. Of flaky tails and itchy skin. Nat. Genet. 41(5), 512-513 (2009).
42. Sugiura H, Ebise H, Tazawa T et al. Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. Br. J. Dermatol. 152(1), 146-149 (2005).
43. Jarzab J, Filipowska B, Zebracka J et al. Locus 1q21 Gene expression changes in atopic dermatitis skin lesions: Deregulation of small proline-rich region 1A. Int. Arch. Allergy Immunol. 151(1), 28-37 (2010).
44. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J. Allergy Clin. Immunol. 124(6), 1235-1244.e58 (2009).
45. Paternoster L, Standl M, Chen CM et al.; Australian Asthma Genetics Consortium (AAGC)Genetics of Overweight Young Adults (GOYA); Consortium; Early Genetics & Lifecourse Epidemiology (EAGLE) Consortium. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat. Genet. 44(2), 187-192 (2011).
46. Meyer-Hoffert U. Reddish, scaly, and itchy: How proteases and their inhibitors contribute to inflammatory skin diseases. Arch. Immunol. Ther. Exp. 57(5), 345-354 (2009).
47. Hansson L, Bäckman A, Ny A et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: A model for chronic itchy dermatitis. J. Invest. Dermatol. 118(3), 444-449 (2002).
48. Vasilopoulos Y, Cork MJ, Murphy R et al. Genetic association between an AACC insertion in the 3′UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J. Invest. Dermatol. 123(1), 62-66 (2004).
49. Voegeli R, Rawlings AV, Breternitz M, Doppler S, Schreier T, Fluhr JW. Increased stratum corneum serine protease activity in acute eczematous atopic skin. Br. J. Dermatol. 161(1), 70-77 (2009).
50. Voegeli R, Doppler S, Joller P, Breternitz M, Fluhr JW, Rawlings AV. Increased mass levels of certain serine proteases in the stratum corneum in acute eczematous atopic skin. Int. J. Cosmet. Sci. 33(6), 560-565 (2011).
51. Walley AJ, Chavanas S, Moffatt MF et al. Gene polymorphism in Netherton and common atopic disease. Nat. Genet. 29(2), 175-178 (2001).
52. Kato A, Fukai K, Oiso N, Hosomi N, Murakami T, Ishii M. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br. J. Dermatol. 148(4), 665-669 (2003).
53. Nishio Y, Noguchi E, Shibasaki M et al. Association between polymorphisms in the SPINK5 gene and atopic dermatitis in the Japanese. Genes Immun. 4(7), 515-517 (2003).
54. Fölster-Holst R, Stoll M, Koch WA, Hampe J, Christophers E, Schreiber S. Lack of association of SPINK5 polymorphisms with nonsyndromic atopic dermatitis in the population of Northern Germany. Br. J. Dermatol. 152(6), 1365-1367 (2005).
55. Hubiche T, Ged C, Benard A et al. Analysis of SPINK 5, KLK 7 and FLG genotypes in a French atopic dermatitis cohort. Acta Derm. Venereol. 87(6), 499-505 (2007).
56. Bonnart C, Deraison C, Lacroix M et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J. Clin. Invest. 120(3), 871-882 (2010).
57. Dubin G. Proteinaceous cysteine protease inhibitors. Cell. Mol. Life Sci. 62(6), 653-669 (2005).
58. Cork MJ, Robinson DA, Vasilopoulos Y et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. J. Allergy Clin. Immunol. 118(1), 3-21; quiz 22 (2006).
59. Grubauer G, Feingold KR, Elias PM. Relationship of epidermal lipogenesis to cutaneous barrier function. J. Lipid Res. 28(6), 746-752 (1987).
60. Jakobza D, Reichmann G, Langnick W, Langnick A, Schulze P. [Surface skin lipids in atopic dermatitis]. Dermatol. Monatsschr. 167(1), 26-29 (1981).
61. Barth J, Gatti S, Jatzke M. Skin surface lipids in atopic eczema and ichthyosis. Chron Derm. 10, 609-612 (1989).
62. Mustakallio KK, Kiistala U, Piha HJ, Nieminen E. Epidermal lipids in Besnier's prurigo (atopic eczema). Ann. Med. Exp. Biol. Fenn. 45(3), 323-325 (1967).
63. Schäfer L, Kragballe K. Abnormalities in epidermal lipid metabolism in 11 patients with atopic dermatitis. J. Invest. Dermatol. 96(1), 10-15 (1991).
64. Melnik BC, Hollmann J, Erler E, Verhoeven B, Plewig G. Microanalytical screening of all major stratum corneum lipids by sequential high-performance thin-layer chromatography. J. Invest. Dermatol. 92(2), 231-234 (1989).
65. Melnik BC, Plewig G. Is the origin of atopy linked to deficient conversion of omega-6-fatty acids to prostaglandin E1? J. Am. Acad. Dermatol. 21(3 Pt 1), 557-563 (1989).
66. Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: An etiologic factor in atopic dry skin? J. Invest. Dermatol. 96(4), 523-526 (1991).
67. Masukawa Y, Narita H, Shimizu E et al. Characterization of overall ceramide species in human stratum corneum. J. Lipid Res. 49(7), 1466-1476 (2008).
68. Ishikawa J, Narita H, Kondo N et al. Changes in the ceramide profile of atopic dermatitis patients. J. Invest. Dermatol. 130(10), 2511-2514 (2010).
69. Jungersted JM, Scheer H, Mempel M et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy 65(7), 911-918 (2010).
70. Holleran WM, Takagi Y, Menon GK et al. Permeability barrier requirements regulate epidermal beta-glucocerebrosidase. J. Lipid Res. 35(5), 905-912 (1994).
71. Jensen JM, Fölster-Holst R, Baranowsky A et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J. Invest. Dermatol. 122, 1423-1431 (2004).
72. Higuchi K, Hara J, Okamoto R, Kawashima M, Imokawa G. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem. J. 350 (Pt 3), 747-756 (2000).
73. Doering T, Holleran WM, Potratz A et al. Sphingolipid activator proteins are required for epidermal permeability barrier formation. J. Biol. Chem. 274(16), 11038-11045 (1999).
74. Nagelkerken L, Verzaal P, Lagerweij T et al. Development of atopic dermatitis in mice transgenic for human apolipoprotein C1. J. Invest. Dermatol. 128(5), 1165-1172 (2008).
75. Proksch E, Jensen JM, Elias PM. Skin lipids and epidermal differentiation in atopic dermatitis. Clin. Dermatol. 21(2), 134-144 (2003).
76. Yamazaki Y, Okawa K, Yano T, Tsukita S, Tsukita S. Optimized proteomic analysis on gels of cell-cell adhering junctional membrane proteins. Biochemistry 47(19), 5378-5386 (2008).
77. Utech M, Brüwer M, Nusrat A. Tight junctions and cell-cell interactions. Methods Mol. Biol. 341, 185-195 (2006).
78. Hadj-Rabia S, Baala L, Vabres P et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: A tight junction disease. Gastroenterology 127(5), 1386-1390 (2004).
79. Furuse M, Hata M, Furuse K et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice. J. Cell Biol. 156(6), 1099-1111 (2002).
80. Turksen K, Troy TC. Permeability barrier dysfunction in transgenic mice overexpressing claudin 6. Development 129(7), 1775-1784 (2002).
81. De Benedetto A, Rafaels NM, McGirt LY et al. Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 127(3), 773-786.e1 (2011).
82. Harder J, Schröder JM. Psoriatic scales: A promising source for the isolation of human skin-derived antimicrobial proteins. J. Leukoc. Biol. 77(4), 476-486 (2005).
83. Ahrens K, Schunck M, Podda GF et al. Mechanical and metabolic injury to the skin barrier leads to increased expression of murine β-defensin-1, -3, and -14. J. Invest. Dermatol. 131(2), 443-452 (2011).
84. Leung DY. Infection in atopic dermatitis. Curr. Opin. Pediatr. 15(4), 399-404 (2003).
85. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347(15), 1151-1160 (2002).
86. Nomura I, Goleva E, Howell MD et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J. Immunol. 171(6), 3262-3269 (2003).
87. Gläser R, Meyer-Hoffert U, Harder J et al. The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. J. Invest. Dermatol. 129(3), 641-649 (2009).
88. Asano S, Ichikawa Y, Kumagai T, Kawashima M, Imokawa G. Microanalysis of an antimicrobial peptide, betadefensin-2, in the stratum corneum from patients with atopic dermatitis. Br. J. Dermatol. 159(1), 97-104 (2008).
89. Gambichler T, Skrygan M, Tomi NS et al. Differential mRNA expression of antimicrobial peptides and proteins in atopic dermatitis as compared to psoriasis vulgaris and healthy skin. Int. Arch. Allergy Immunol. 147(1), 17-24 (2008).
90. Ballardini N, Johansson C, Lilja G et al. Enhanced expression of the antimicrobial peptide LL-37 in lesional skin of adults with atopic eczema. Br. J. Dermatol. 161(1), 40-47 (2009).
91. Harder J, Dressel S, Wittersheim M et al. Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J. Invest. Dermatol. 130(5), 1355-1364 (2010).
92. Jensen JM, Ahrens K, Meingassner J et al. Differential suppression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids. Exp. Dermatol. 20(10), 783-788 (2011).
93. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: A disease caused by innate immune defects? J. Invest. Dermatol. 129, 14-30 (2009).
94. Maintz L, Novak N. Modifications of the innate immune system in atopic dermatitis. J. Innate Immun. 3(2), 131-141 (2011).
95. Maibach HI. In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy. Dermatologica 152(Suppl. 1), 11-25 (1976).
96. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res. Technol. 7(2), 73-77 (2001).
97. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J. Am. Acad. Dermatol. 54(1), 1-15; quiz 16 (2006).
98. Aschoff R, Schwanebeck U, Bräutigam M, Meurer M. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. Exp. Dermatol. 18(1), 24-29 (2009).
99. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stütz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Br. J. Dermatol. 137(4), 568-576 (1997).
100. Malinowski M, Martus P, Lock JF, Neuhaus P, Stockmann M. Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function. Transpl. Int. 24(2), 184-193 (2011).
101. Lodén M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br. J. Dermatol. 140(2), 264-267 (1999).
102. Mitschenko AV, Niemeier V, Proksch E, Gieler U. Die lokaltherapie der atopischen dermatitis mit emollienzien. Thieme Drug Report 3, 1-12 (2009).